Cantini F - Search Results

1

A case report of Takayasu arteritis with history of retro-peritoneal fibrosis and coeliac disease: An unusual association.

Benucci M, Manfredi M, Michelagnoli S, Bertelli A, Cantini F. Benucci M, et al. Among authors: cantini f. Clin Exp Rheumatol. 2006 Mar-Apr;24(2 Suppl 41):S104-5. Clin Exp Rheumatol. 2006. PMID: 16859608 No abstract available.

2

Disease activity and antinucleosome antibodies in systemic lupus erythematosus.

Benucci M, Gobbi FL, Del Rosso A, Cesaretti S, Niccoli L, Cantini F. Benucci M, et al. Among authors: cantini f. Scand J Rheumatol. 2003;32(1):42-5. doi: 10.1080/03009740310000391. Scand J Rheumatol. 2003. PMID: 12635945

3

Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.

Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F. Niccoli L, et al. Among authors: cantini f. Rheumatology (Oxford). 2007 Jul;46(7):1161-4. doi: 10.1093/rheumatology/kem101. Epub 2007 May 3. Rheumatology (Oxford). 2007. PMID: 17478466

4

Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?

Cantini F, Benucci M. Cantini F, et al. Ann Rheum Dis. 2019 Apr;78(4):e23. doi: 10.1136/annrheumdis-2017-212820. Epub 2017 Dec 29. Ann Rheum Dis. 2019. PMID: 29288210 No abstract available.

5

Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke.

Cantini F, Benucci M. Cantini F, et al. Ann Rheum Dis. 2019 Apr;78(4):e25. doi: 10.1136/annrheumdis-2018-213044. Epub 2018 Feb 2. Ann Rheum Dis. 2019. PMID: 29420201 No abstract available.

6

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Cantini F, Benucci M. Cantini F, et al. Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018. Biologics. 2018. PMID: 30214149 Free PMC article. Review.

7

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching.

Cantini F, Benucci M. Cantini F, et al. Ann Rheum Dis. 2020 Feb;79(2):e13. doi: 10.1136/annrheumdis-2018-214757. Epub 2018 Nov 28. Ann Rheum Dis. 2020. PMID: 30487149 No abstract available.

8

Non-medical switching: save today and pay tomorrow.

Benucci M, Cantini F. Benucci M, et al. Among authors: cantini f. J Med Econ. 2019 Nov;22(11):1160-1161. doi: 10.1080/13696998.2019.1651132. Epub 2019 Sep 9. J Med Econ. 2019. PMID: 31364882 Free article. No abstract available.

9

Therapeutic Potential of Ixekizumab in the Treatment of Ankylosing Spondylitis: A Review on the Emerging Clinical Data.

Benucci M, Damiani A, Li Gobbi F, Grossi V, Infantino M, Manfredi M, Niccoli L, Cantini F. Benucci M, et al. Among authors: cantini f. Ther Clin Risk Manag. 2020 Apr 16;16:287-297. doi: 10.2147/TCRM.S228880. eCollection 2020. Ther Clin Risk Manag. 2020. PMID: 32368068 Free PMC article. Review.

10

Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis.

Salvarani C, Cantini F, Boiardi L, Hunder GG. Salvarani C, et al. Among authors: cantini f. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S23-8. Clin Exp Rheumatol. 2003. PMID: 14740424 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

316 results

Search Page

Filters